DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS: ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND ITS COMPONENTS

被引：0
|
作者：
Kavanaugh, A. [1 ]
Coates, L. [2 ]
Merola, J. F. [3 ]
Mease, P. J. [4 ,5 ]
Nowak, M. [6 ]
Banerjee, S. [7 ]
Hippeli, L. [8 ]
Lehman, T. [9 ]
机构：
[1] Univ Calif San Diego, Rheumatol, La Jolla, CA 92093 USA
[2] Univ Oxford, Orthopaed Rheumatol & Musculoskeletal Sci, Oxford, England
[3] Harvard Med Sch, Brigham & Womens Hosp, Dermatol, Boston, MA 02115 USA
[4] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[5] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA
[6] Bristol Myers Squibb, Clin R&D, Princeton, NJ USA
[7] Bristol Myers Squibb, Rheumatol & Dermatol, Princeton, NJ USA
[8] Bristol Myers Squibb, Biostats, Princeton, NJ USA
[9] Bristol Myers Squibb, WW Med Immunol, Princeton, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1849
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1039
引用
收藏
页码：835 / 835
页数：1
相关论文
共 50 条
  • [1] Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components
    Kavanaugh, Arthur
    Coates, Laura
    Merola, Joseph
    Mease, Philip J.
    Nowak, Miroslawa
    Banerjee, Subhashis
    Hippeli, Lauren
    Lehman, Tom
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4235 - 4236
  • [2] Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
    Kavanaugh, Arthur
    Coates, Laura C.
    Mease, Philip J.
    Nowak, Miroslawa
    Hippeli, Lauren
    Lehman, Thomas
    Banerjee, Subhashis
    Merola, Joseph F.
    RHEUMATOLOGY, 2024,
  • [3] Lupus Low Disease Activity State (LLDAS) Achievement with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE
    Morand, Eric
    Hobar, Coburn
    Pomponi, Samantha
    Koti, Ravi
    Wegman, Thomas
    van Vollenhoven, Ronald
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2961 - 2963
  • [4] BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS
    Fitzgerald, O.
    Gladman, D. D.
    Mease, P. J.
    Ritchlin, C. T.
    Smolen, J. S.
    Gao, L.
    Hu, S.
    Nowak, M.
    Banerjee, S.
    Catlett, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 215 - 216
  • [5] Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis
    FitzGerald, Oliver
    Gladman, Dafna
    Mease, Philip J.
    Ritchlin, Christopher
    Smolen, Josef
    Gao, Lu
    Hu, Sarah
    Nowak, Miroslawa
    Banerjee, Subhashis
    Catlett, Ian M.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4229 - 4230
  • [6] Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters - Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis
    Fleischmann, Roy
    Thaci, Diamant
    Gooderham, Melinda
    Strober, Bruce
    Korman, Neil J.
    Banerjee, Subhashis
    Lehman, Tom
    Nowak, Miroslawa
    Sreih, Antoine
    Morita, Akimichi
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4227 - 4228
  • [7] SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS - RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS
    Fleischmann, R. M.
    Thaci, D.
    Gooderham, M.
    Strober, B.
    Korman, N. J.
    Banerjee, S.
    Lehman, T.
    Nowak, M.
    Sreih, A.
    Morita, A.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 835 - 836
  • [8] Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial
    Eder, Lihi
    Ogdie, Alexis R.
    Banerjee, Subhashis
    Nowak, Miroslawa
    Lehman, Thomas
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 945 - 947
  • [9] SAFETY AND EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A RANDOMISED PHASE 2 TRIAL
    Mease, P. J.
    Deodhar, A.
    Van der Heijde, D.
    Behrens, F.
    Kivitz, A.
    Neal, J.
    Nys, M.
    Lehman, T.
    Delev, N.
    Korish, S.
    Nowak, M.
    Banerjee, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 842 - 843
  • [10] Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
    Mease, Philip J.
    Deodhar, Atul
    van der Heijde, Desiree
    Behrens, Frank
    Kivitz, Alan
    Neal, Jeffrey
    Nys, Marleen
    Lehman, Tom
    Delev, Nikolay
    Korish, Shimon
    Nowak, Miroslawa
    Banerjee, Subhashis
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3167 - 3168
12345